Arcus CMO Bill Grossman moves to Gilead; Kartik Krishnan takes over clinical development

Arcus Biosciences, Inc.

Bill Grossman, MD, PhD, resigns as CMO effective July 26, 2021, to become SVP of Oncology Clinical Research at Gilead.
Grossman will be Arcus's point of contact at Gilead for co-development activities under the alliance.
Kartik Krishnan, MD, PhD, promoted to lead Arcus clinical development, effective July 26.
Grossman will provide consulting to Arcus for up to 3 months; his stock option exercise period extended to July 1, 2022.
Krishnan joined Arcus in 2019 and has been assuming increasing responsibilities since December 2020.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bill Grossman

Chief Medical Officer

RCUS · Arcus Biosciences, Inc.

Effective: 2021-07-26
Filed: July 19, 2021, 7:59 PM ET

On July 16, 2021, Bill Grossman, MD, Arcus Biosciences, Inc.’s Chief Medical Officer, resigned from Arcus to become SVP of Oncology Clinical Research at Gilead Sciences, Inc., effective July 26, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bill Grossman resigned as Chief Medical Officer at Arcus Biosciences, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On July 16, 2021, Bill Grossman, MD, Arcus Biosciences, Inc.’s Chief Medical Officer, resigned from Arcus to become SVP of Oncology Clinical Research at Gilead Sciences, Inc., effective July 26, 2021.

View on SEC.gov

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-037042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.